Media ReleasesLBT Innovations

View All LBT Innovations News


LBT Innovations - Quarterly Activities/Appendix 4C Cash Flow Report


Adelaide, Australia, 27 January 2022: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence, is pleased to release its Appendix 4C – Quarterly Cashflow report and business update for the quarter ended 31 December 2021 (the Quarter). All financial results are in Australian dollars and are unaudited.

Key Highlights

  • Transformational acquisition of Clever Culture Systems Joint Venture
  • FDA Clearance for MRSA analysis module – available for customers in the United States
  • 10 Advanced sales opportunities, back-to-back product evaluations completed in Europe
  • 31 December 2021 cash balance of $6.3 million after settlement of the CCS acquisition
For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.